Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NGF-574H
- Development stage
- Unknown
- Lead developer
- Medipost
- Administration
- Topical
01
Overview
NGF-574H is a topical hair serum developed to treat androgenic alopecia (pattern hair loss). It is a **conditioned medium** of human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs). These stem cells are exposed in vitro to an environment mimicking alopecia to prime the secretion of paracrine factors (growth factors, cytokines, and trophic factors) that promote hair growth. The serum is formulated at 5% concentration of this conditioned media and is used topically on the scalp twice daily. Clinical trials in Asian adults have shown improvements in hair density, hair diameter, and hair growth after 16-24 weeks of use[1][2][3][4][5][6][7].
- Brand names
- Celino NGF-574H
- Other names
- NGF574HNGF-574HNGF 574H
Beyond the preview
Go deeper on NGF-574H.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NGF-574H.